

# Mattias Ekstedt

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5072296/mattias-ekstedt-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

73  
papers

6,113  
citations

27  
h-index

78  
g-index

80  
ext. papers

8,116  
ext. citations

5.9  
avg, IF

5.74  
L-index

#	Paper	IF	Citations
73	Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events.. <i>Journal of Hepatology</i> , <b>2022</b> ,	13.4	3
72	Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance.. <i>JHEP Reports</i> , <b>2022</b> , 4, 100409	10.3	4
71	Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease.. <i>Journal of Hepatology</i> , <b>2021</b> ,	13.4	4
70	Low awareness of non-alcoholic fatty liver disease in patients with type 2 diabetes in Swedish Primary Health Care. <i>Scandinavian Journal of Gastroenterology</i> , <b>2021</b> , 1-10	2.4	0
69	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2021</b> ,	24.2	37
68	Disease Progression Modeling for Economic Evaluation in Nonalcoholic Fatty Liver Disease-A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9	1
67	Bariatric Surgery Versus Standard Obesity Treatment and the Risk of Severe Liver Disease: Data From the Swedish Obese Subjects Study. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 2675-2676.e2	6.9	1
66	A Dynamic Aspartate-to-Alanine Aminotransferase Ratio Provides Valid Predictions of Incident Severe Liver Disease. <i>Hepatology Communications</i> , <b>2021</b> , 5, 1021-1035	6	5
65	Reply to: "Rationale of adding muscle volume to muscle fat infiltration in the definition of an adverse muscle composition is unclear". <i>JHEP Reports</i> , <b>2021</b> , 3, 100257	10.3	1
64	European NAFLD Preparedness Index: Is Europe ready to meet the challenge of fatty liver disease?. <i>JHEP Reports</i> , <b>2021</b> , 3, 100234	10.3	13
63	Non-alcoholic fatty liver disease does not increase dementia risk although histology data might improve risk prediction. <i>JHEP Reports</i> , <b>2021</b> , 3, 100218	10.3	3
62	Evaluating the prevalence and severity of NAFLD in primary care: the EPSONIP study protocol. <i>BMC Gastroenterology</i> , <b>2021</b> , 21, 180	3	2
61	Risk for hepatic and extra-hepatic outcomes in nonalcoholic fatty liver disease. <i>Journal of Internal Medicine</i> , <b>2021</b> ,	10.8	1
60	Moderate alcohol consumption is associated with advanced fibrosis in non-alcoholic fatty liver disease and shows a synergistic effect with type 2 diabetes mellitus. <i>Metabolism: Clinical and Experimental</i> , <b>2021</b> , 115, 154439	12.7	10
59	Adverse muscle composition is linked to poor functional performance and metabolic comorbidities in NAFLD. <i>JHEP Reports</i> , <b>2021</b> , 3, 100197	10.3	14
58	Morbidity, risk of cancer and mortality in 3645 HFE mutations carriers. <i>Liver International</i> , <b>2021</b> , 41, 545-553	7.9	4
57	Serum levels of endotrophin are associated with nonalcoholic steatohepatitis. <i>Scandinavian Journal of Gastroenterology</i> , <b>2021</b> , 56, 437-442	2.4	1

56	Low hepatic manganese concentrations in patients with hepatic steatosis - A cohort study of copper, iron and manganese in liver biopsies. <i>Journal of Trace Elements in Medicine and Biology</i> , <b>2021</b> , 67, 126772	4.1	2
55	Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , <b>2021</b> , 75, 770-785	13.4	19
54	The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?. <i>Journal of Hepatology</i> , <b>2021</b> ,	13.4	7
53	Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease.. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> ,	5.6	2
52	Bleeding complications with clopidogrel or ticagrelor in ST-elevation myocardial infarction patients - A real life cohort study of two treatment strategies. <i>IJC Heart and Vasculature</i> , <b>2020</b> , 27, 100495	2.4	4
51	Established and emerging factors affecting the progression of nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , <b>2020</b> , 111S, 154183	12.7	21
50	The amount of liver fat predicts mortality and development of type 2 diabetes in non-alcoholic fatty liver disease. <i>Liver International</i> , <b>2020</b> , 40, 1069-1078	7.9	11
49	Modifiers of Liver-Related Manifestation in the Course of NAFLD. <i>Current Pharmaceutical Design</i> , <b>2020</b> , 26, 1062-1078	3.3	3
48	Cardiorespiratory fitness, muscular strength, and obesity in adolescence and later chronic disability due to cardiovascular disease: a cohort study of 1 million men. <i>European Heart Journal</i> , <b>2020</b> , 41, 1503-1510	9.5	30
47	Health Care Costs of Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease Are Nearly Twice Those of Matched Controls. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 1592-1599.e8	6.9	5
46	The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. <i>Contemporary Clinical Trials</i> , <b>2020</b> , 98, 106175	2.3	28
45	Biomarkers of liver fibrosis: prospective comparison of multimodal magnetic resonance, serum algorithms and transient elastography. <i>Scandinavian Journal of Gastroenterology</i> , <b>2020</b> , 55, 848-859	2.4	4
44	Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. <i>Science Translational Medicine</i> , <b>2020</b> , 12,	17.5	51
43	Commentary: Nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name. <i>Metabolism: Clinical and Experimental</i> , <b>2020</b> , 113, 154413	12.7	16
42	A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe. <i>Journal of Hepatology</i> , <b>2020</b> , 72, 14-24	13.4	75
41	Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 505-515	13.4	113
40	Model-inferred mechanisms of liver function from magnetic resonance imaging data: Validation and variation across a clinically relevant cohort. <i>PLoS Computational Biology</i> , <b>2019</b> , 15, e1007157	5	4
39	Collagen proportionate area is an independent predictor of long-term outcome in patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 1214-1222	6.1	28

38	Accuracy of Noninvasive Scoring Systems in Assessing Risk of Death and Liver-Related Endpoints in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 1148-1156.e4	6.9	38
37	Assessing the disease burden of non-alcoholic fatty liver disease in the real world - big data and big numbers. <i>BMC Medicine</i> , <b>2019</b> , 17, 123	11.4	4
36	PNPLA3 variant M148 causes resistance to starvation-mediated lipid droplet autophagy in human hepatocytes. <i>Journal of Cellular Biochemistry</i> , <b>2019</b> , 120, 343-356	4.7	33
35	Liver R2* is affected by both iron and fat: A dual biopsy-validated study of chronic liver disease. <i>Journal of Magnetic Resonance Imaging</i> , <b>2019</b> , 50, 325-333	5.6	13
34	Cardiovascular risk factors in non-alcoholic fatty liver disease. <i>Liver International</i> , <b>2019</b> , 39, 197-204	7.9	42
33	Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long-term follow-up study. <i>Hepatology Communications</i> , <b>2018</b> , 2, 48-57	6	106
32	Natural history of nonalcoholic fatty liver disease: A prospective follow-up study with serial biopsies. <i>Hepatology Communications</i> , <b>2018</b> , 2, 199-210	6	66
31	Bleeding complications after myocardial infarction in a real world population - An observational retrospective study with a sex perspective. <i>Thrombosis Research</i> , <b>2018</b> , 167, 156-163	8.2	6
30	Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. <i>Hepatology</i> , <b>2017</b> , 65, 1557-1565	11.2	796
29	Using a 3% Proton Density Fat Fraction as a Cut-Off Value Increases Sensitivity of Detection of Hepatic Steatosis, Based on Results From Histopathology Analysis. <i>Gastroenterology</i> , <b>2017</b> , 153, 53-55.e7	13.3	39
28	Automated quantification of steatosis: agreement with stereological point counting. <i>Diagnostic Pathology</i> , <b>2017</b> , 12, 80	3	8
27	Natural History of NAFLD/NASH. <i>Current Hepatology Reports</i> , <b>2017</b> , 16, 391-397	1	62
26	Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 1265-1273	13.4	423
25	SAF score and mortality in NAFLD after up to 41 years of follow-up. <i>Scandinavian Journal of Gastroenterology</i> , <b>2017</b> , 52, 87-91	2.4	24
24	Low to moderate lifetime alcohol consumption is associated with less advanced stages of fibrosis in non-alcoholic fatty liver disease. <i>Scandinavian Journal of Gastroenterology</i> , <b>2017</b> , 52, 159-165	2.4	35
23	Development of Serum Marker Models to Increase Diagnostic Accuracy of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: The New LINKI Algorithm Compared with Established Algorithms. <i>PLoS ONE</i> , <b>2016</b> , 11, e0167776	3.7	12
22	Reply. <i>Hepatology</i> , <b>2016</b> , 64, 310-1	11.2	
21	Elevated serum ferritin is associated with increased mortality in non-alcoholic fatty liver disease after 16 years of follow-up. <i>Liver International</i> , <b>2016</b> , 36, 1688-1695	7.9	31

20	Contrast-enhanced ultrasonography could be a non-invasive method for differentiating none or mild from severe fibrosis in patients with biopsy proven non-alcoholic fatty liver disease. <i>Scandinavian Journal of Gastroenterology</i> , <b>2016</b> , 51, 1126-32	2.4	9
19	Soluble urokinase plasminogen activator receptor levels are associated with severity of fibrosis in nonalcoholic fatty liver disease. <i>Translational Research</i> , <b>2015</b> , 165, 658-66	11	22
18	Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. <i>Hepatology</i> , <b>2015</b> , 61, 1547-54	11.2	1158
17	Littoral cell angioma in a patient with Crohn's disease. <i>Case Reports in Gastrointestinal Medicine</i> , <b>2015</b> , 2015, 474969	0.6	4
16	A Novel SMAD4 Mutation Causing Severe Juvenile Polyposis Syndrome with Protein Losing Enteropathy, Immunodeficiency, and Hereditary Haemorrhagic Telangiectasia. <i>Case Reports in Gastrointestinal Medicine</i> , <b>2015</b> , 2015, 140616	0.6	5
15	Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. <i>PLoS Medicine</i> , <b>2014</b> , 11, e1001680	11.6	363
14	Pinworm infestation mimicking Crohn's disease. <i>Case Reports in Gastrointestinal Medicine</i> , <b>2013</b> , 2013, 706197	0.6	4
13	High prevalence of autoantibodies to C-reactive protein in patients with chronic hepatitis C infection: association with liver fibrosis and portal inflammation. <i>Human Immunology</i> , <b>2012</b> , 73, 382-8	2.3	18
12	Low clinical relevance of the nonalcoholic fatty liver disease activity score (NAS) in predicting fibrosis progression. <i>Scandinavian Journal of Gastroenterology</i> , <b>2012</b> , 47, 108-15	2.4	39
11	Resistin is associated with breach of tolerance and anti-nuclear antibodies in patients with hepatobiliary inflammation. <i>Scandinavian Journal of Immunology</i> , <b>2011</b> , 74, 463-70	3.4	9
10	Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease. <i>Scandinavian Journal of Gastroenterology</i> , <b>2009</b> , 44, 366-74	2.4	131
9	Separation of advanced from mild fibrosis in diffuse liver disease using 31P magnetic resonance spectroscopy. <i>European Journal of Radiology</i> , <b>2008</b> , 66, 313-20	4.7	34
8	Histological progression of non-alcoholic fatty liver disease: a critical reassessment based on liver sampling variability. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2007</b> , 26, 821-30	6.1	43
7	Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. <i>Journal of Hepatology</i> , <b>2007</b> , 47, 135-41	13.4	211
6	Long-term follow-up of patients with NAFLD and elevated liver enzymes. <i>Hepatology</i> , <b>2006</b> , 44, 865-73	11.2	1699
5	Development of an unbiased method for the estimation of liver steatosis. <i>Clinical Transplantation</i> , <b>2005</b> , 19, 571; author reply 572	3.8	1
4	Semiquantitative evaluation overestimates the degree of steatosis in liver biopsies: a comparison to stereological point counting. <i>Modern Pathology</i> , <b>2005</b> , 18, 912-6	9.8	87
3	Digital twin predicting diet response before and after long-term fasting		1

2 Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease 1

1 Non-invasive diagnosis and staging of non-alcoholic fatty liver disease. *Hormones*, 3.1 0